Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Takeda Global Research & Development Center, Inc. H. Lundbeck A/S |
---|---|
Information provided by: | Takeda Global Research & Development Center, Inc. |
ClinicalTrials.gov Identifier: | NCT00734071 |
The purpose of this study is to determine the safety and efficacy of Lu AA21004 in Treating Generalized Anxiety Disorder.
Condition | Intervention | Phase |
---|---|---|
Generalized Anxiety Disorder |
Drug: Lu AA21004 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder |
Enrollment: | 457 |
Study Start Date: | June 2008 |
Study Completion Date: | February 2009 |
Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Lu AA21004
Lu AA21004 5 mg, tablets, orally, once daily for up to 8 weeks.
|
2: Placebo Comparator |
Drug: Lu AA21004
Lu AA21004 placebo-matching tablets, orally, once daily for up to 8 weeks.
|
Generalized anxiety disorder is associated with considerable personal stress as well as substantial social and functional impairment. It is characterized by excessive anxiety and uncontrollable worry that persist for longer than 6 months. Typically these worries are related to activities that are common to daily life events.
Furthermore, patients with generalized anxiety disorder suffer from at least 3 of the following symptoms:
restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and impaired sleep cycle. Patients with generalized anxiety disorder also suffer from many somatic symptoms such as palpitation, fast pulse, sweating, dyspnea, pain, nausea, dry mouth, and dizziness. Generalized anxiety disorder affects about 6.8 million American adults, including twice as many women as men. The disorder develops gradually and can begin at any point in the life cycle, although years of highest risk are between childhood and middle age. There is evidence that genes play a modest role in the disorder. About 12% of the patients in anxiety disorder clinics have generalized anxiety disorder, making it the most common diagnosis. In comparison with other anxiety disorders, generalized anxiety disorder is 4 times more prevalent than panic disorder and 3 times more prevalent than simple phobia. An estimate one-third of people with generalized anxiety disorder have no other comorbid diagnosis.
Lu AA21004 is a compound under development by Takeda Pharmaceutical Company Limited and H. Lundbeck A/S for the treatment of generalized anxiety disorder. Lu AA21004 combines serotonin enhancement with 5-hydroxytryptamine-1A partial agonism and affinity for the 5-hydroxytryptamine-3 receptor.
This aim of this phase 3 study is to investigate the efficacy and safety of a fixed dose of 5 mg Lu AA21004 QD in the treatment of generalized anxiety disorder.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Has 1 or more of the following:
Study Director: | Sr. Medical Director | Takeda Global Research & Development Center, Inc. |
Responsible Party: | Takeda Global Research & Development Center, Inc. ( Sr VP, Clinical Science ) |
Study ID Numbers: | Lu AA21004_310 |
Study First Received: | August 11, 2008 |
Last Updated: | June 22, 2009 |
ClinicalTrials.gov Identifier: | NCT00734071 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Generalized Anxiety Disorder Mood Disorder Affective Disorder Anxiety Disorder Drug Therapy |
Anxiety Disorders Mental Disorders Mood Disorders |
Pathologic Processes Disease Anxiety Disorders Mental Disorders |